Sentences with phrase «cell therapy against»

Spark Therapeutics hopes to win U.S. approval in January 2018 for a gene therapy to cure a rare inherited form of blindness, while Novartis could get a U.S. go - ahead as early as next month for its gene - modified cell therapy against leukaemia - a variation on standard gene therapy.

Not exact matches

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.

Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.

Antibodies and T cells against the protein could cause the immune system to attack cells carrying it, making gene therapy ineffective.

Just as chemotherapy often requires several drugs to combat resistance in cancerous cells, successful antimicrobial therapy against some pathogens requires a combination of drugs.

Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have developed an alternative treatment in which virus - specific cells protect patients against severe, drug - resistant viral infections.

It showed effectiveness against liver cancer in a phase II clinical trial and will move into a phase III trial later this year, David Kirn, an oncologist and the company's president and chief executive officer, said at a recent meeting of the American Society for Gene & Cell Therapy in Washington, D.C..

The authors said their results, which they have made publicly available, constitute an invaluable resource to help clinicians predict which chemotherapies will be most effective against tumor cells with particular genetic mutations, and how to rationally combine therapies to prevent cancers from developing resistance.

By viewing this fusion as another disease imposed onto tumor cells, scientists could devise new therapies against metastasis, the researchers say in the May Nature Reviews Cancer.

Using an experimental DNA - based therapy, scientists might slow the self - destructive immune reaction against insulin - making cells that causes type 1 diabetes.

Therefore, the insights of Dr. Melendez and her colleagues may deepen our understanding of cancer and aid in the development of therapies against malignant cell growth.

For patients, down the road Dr. Ohashi envisions a new era of combined therapies to simultaneously target and kill these suppressive cells while augmenting the immune response against cancer.

By tracking and understanding which host cell pathways are manipulated by these T. gondii proteins, scientists can identify potential new targets to develop more effective therapies against highly aggressive solid tumors.

Kole Roybal is the 2018 grand prize winner of the inaugural Sartorius & Science Prize for Regenerative Medicine & Cell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the diseCell Therapy, for developing a new class of T cell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disecell immunotherapies that can be fine - tuned to better help the immune system recognize cancer and initiate precise therapeutic action against the disease.

They are examining every aspect of cell function and cell structure, looking for clusters of phenotypes that could label a patient's cancer so precisely that it could be linked to therapies proven effective against just that type.

«Given these results in cells and mice, it may be worthwhile to consider that patients receiving, or who may receive, Amphotericin B - based therapies be appropriately vaccinated against influenza virus.

In the present study, the scientists demonstrated that the drug BI-97D6 increased cancer cell death caused by mda - 7 / IL - 24, and it also helped defend against resistance to the viral gene therapy.

To harness the power of bacteriophages and develop effective therapies against bacteria like C.diff, scientists need to know exactly how these viruses destroy bacterial cell walls.

Cruse and Metcalfe tested their therapy on mast cells in vitro — where it eliminated activation of mast cells by allergen — and against allergic dermatitis in vivo, using a mouse model.

Experimental therapies using T cells taken from the bloodstream have not, however, worked very well against solid tumors.

Therapies based on immune cells, which target particular tumor molecules, are more specific, but they are not effective against a variety of tumors.

Neoantigens are molecules on cell's surfaces that are produced by DNA mutations that are present in cancer cells but not in normal cells, making neoantigens ideal targets for immune therapy against cancer, say the scientists.

The safe use of a stem - cell - based therapy against brain metastasis would require preventing the engineered cells from persisting within the brain, where they could affect normal tissue and possibly give rise to new tumors.

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve - Rosemont Hospital Research Centre, has identified a key new mechanism that regulates the ability of T - cells of the immune system to react against foreign antigens and cancer.

They also identified targets for potential therapies: bolstering levels of either a particular chaperone or a growth factor in brain cells can protect against the toxic effects of misfolded proteins.

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

It's only three patients on a low dose of cells, but San Diego - based Poseida said the results — activity against the cancer and no «cytokine storm» side effects that often come with CAR - T therapy — were good enough to step up to the next dose.

He added: «Truly naive human ES cell lines would not only help answer fundamental questions about how we are made, and be useful for drug screening and tissue therapy, but they would also provide a benchmark against which other types of stem cells could be measured in terms of their effectiveness in stem cell therapy and regenerative medicine.»

Dr. Semenza's research interests include the molecular mechanisms of oxygen homeostasis; gene and stem cell therapy for ischemic cardiovascular disease; the role of HIF - 1 in cancer; and protection of the heart against ischemia - reperfusion injury.

CAR T - cell therapy was also named as the American Society of Clinical Oncology's Advance of the Year in its Clinical Cancer Advances 2018: ASCO's Annual Report on Progress Against Cancer.

These therapies use non-specific molecules that do not affect the cancer directly, but send signals that stimulate other cells of the immune system to fight against cancer cells.

This new therapy works well against B - cell acute lymphomblastic leukemia, a cancer of the blood system, which has led the U.S. Food and Drug Administration to expedite approval of the first CAR - T treatment for children and young adults.

New research into CAR - T cell therapy has revealed crucial mechanisms that could help the immunotherapy technique, which is currently only effective against blood cancers, be adapted for the treatment of brain tumors and other forms of solid cancers.

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B - cell lymphomas.

In contrast, increasing progranulin levels via gene therapy effectively lowered amyloid beta levels, protecting against cell toxicity and reversing the cognitive deficits typically seen in these Alzheimer's models.

This may be the first time a therapy has been directed against the disorganized nature of cancer cells.»

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

Through a joint UNC School of Medicine - NC State research project shows how to harvest lung stem cells non-invasively and then multiply healthy cells — a potentially powerful therapy against inflammatory lung conditions.

Adults with advanced renal cell carcinoma after targeted therapy against vascular endothelial growth factor (VEGF)

Through a joint UNC School of Medicine - NC State research project shows how to harvest lung stem cells non-invasively and then multiply healthy cells — a potential powerful therapy against inflammatory lung conditions.

Radiation therapy can help extend the lives of affected dogs, but also is ineffective against tumor cells that have metastasized.

«We were banging our heads against the wall and this stem cell therapy was a last resort.»